Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 301

Veracyte Announces Launch of New Afirma Xpression Atlas at 2018 AACE Congress

Posted by fidest press agency su lunedì, 21 Mag 2018

Veracyte, Inc. (Nasdaq: VCYT) today announced the launch of the new Afirma Xpression Atlas, an RNA sequencing-based test that provides extensive genomic information to aid in surgery and treatment decisions for patients with potentially cancerous thyroid nodules. The new test is being introduced at the AACE 27th Annual Scientific & Clinical Congress where robust test performance data will be shared in a Product Theater event and poster presentation by Veracyte and external researchers. The AACE meeting is being held May 16-20 in Boston.
The Afirma Xpression Atlas detects 761 DNA variants and 130 RNA fusion pairs in over 500 genes that have been linked to thyroid cancer. In some cases, these gene alterations have demonstrated association with more aggressive thyroid cancers or with higher-stage disease.
“For patients who are already going to surgery for suspected thyroid cancer, the Afirma Xpression Atlas provides additional genomic information that physicians and patients may use in decisions about the surgical approach,” said Peter M. Sadow, M.D., Ph.D., of Massachusetts General Hospital and Harvard Medical School. “Additionally, as more is understood about gene alterations and their impact on thyroid cancer development, prognosis and tumor pathway dependence, this RNA sequencing information may help to further guide patient care.” Dr. Sadow will present performance data for the Xpression Atlas test during a poster session at the AACE meeting on Saturday, May 19. The gene variants and fusion partners in the Afirma Xpression Atlas were derived from the thyroid literature and from The Cancer Genome Atlas (TCGA). The RNA-sequencing based panel is offered as an extension to Veracyte’s market-leading Afirma Genomic Sequencing Classifier (GSC), which is widely used to identify benign nodules among those deemed indeterminate by cytopathology so that patients can avoid unnecessary surgery.“In tandem with our Afirma GSC, the Afirma Xpression Atlas provides physicians with the most comprehensive and evidence-based genomic information available to inform diagnosis, stratify thyroid cancer risk and, for those who are diagnosed with cancer, aid in therapeutic selection,” said Bonnie Anderson, Veracyte’s chairman and chief executive office.

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: